Items where Author is "Smith, Richard"

In Press

Smith, RD The 'prominence effect' on contingent valuation. Journal of Economic Psychology. (In Press)

Smith, RD, Drager, N, Hardimann, M and Keogh-Brown, MR Assessing the economic impact of SARS: A two-year update. In: The rapid assessment of the economic impact of public health emergencies of international concern. Oxford University Press. (In Press)

Published

Smith, RD (2008) Contingent valuation in health care: does it matter how the 'good' is described. Health Economics, 17 (5). pp. 607-617.

Smith, RD (2007) The relationship between reliability and size of willingness-to-pay values: a qualitative insight. Health Economics, 16 (2). pp. 211-6.

Smith, RD (2007) The role of 'reference goods' in contingent valuation: should we help respondents to 'construct' their willingness to pay? Health Economics, 16 (12). pp. 1319-1322.

Smith, RD (2007) Use, option and externality values: are contingent valuation studies in health care mis-specified? Health Economics, 16 (8). pp. 861-869.

Covey, J and Smith, RD (2006) How common is the 'prominence effect'? Additional evidence to Whynes et al. Health Economics, 15 (2). pp. 205-210.

Smith, RD (2006) Trade in the Health Services: current challenges and future prospects of globalization. In: The Elgar Companion to Health Economics. Edward Elgar, pp. 164-175. ISBN 1845420039

Smith, RD (2006) Responding to global infectious disease outbreaks: Lessons from SARS on the role of risk perception, communication and management. Social Science and Medicine, 63 (12). pp. 3113-3123.

Smith, RD (2006) It's not just what you do, it's the way that you do it: the effect of different payment card formats and survey administration on willingness to pay for health gain. Health Economics, 15 (3). pp. 281-293.

Smith, RD (2006) Trade and public health: facing the challenges of globalisation. Journal of Epidemiology and Community Health, 60 (8). pp. 650-1.

Smith, RD, Yago, M, Millar, M and Coast, J (2006) A Macroeconomic Approach to Evaluating Policies to Contain Antimicrobial Resistance: A Case Study of Methicillin-Resistant Staphylococcus aureus (MRSA). Applied Health Economics and Health Policy, 5 (1). pp. 55-65.

Yeung, RY, Smith, RD, Ho, LM, Johnston, JM and Leung, GM (2006) Empirical implications of response acquiescence in discrete-choice contingent valuation. Health Economics, 15 (10). pp. 1077-1089.

Blouin, C, Drager, N and Smith, RD (2005) International Trade in Health Services and the Gats: Current Issues and Debates. World Bank Publications. ISBN 0821362119

Gobrecht, J, Smith, RD and Drager, N (2005) Measuring Trade in Health Services. In: International Trade in Health Services and the GATS. Oxford University Press. ISBN 0821362119

Smith, RD (2005) Sensitivity to scale in contingent valuation: the importance of the budget constraint. Journal of Health Economics, 24 (3). pp. 515-529.

Smith, RD, Drager, N and Blouin, C (2005) Trade in Health Services and the GATS: an introduction and summary. In: International Trade in Health Services and the GATS. Oxford University Press, pp. 1-16. ISBN 0821362119

Smith, RD, Yago, M, Millar, M and Coast, J (2005) Assessing the macroeconomic impact of a healthcare problem: the application of computable general equilibrium analysis to antimicrobial resistance. Journal of Health Economics, 24 (6). pp. 1055-1075.

Yeung, RY and Smith, RD (2005) Can we use contingent valuation to assess the demand for childhood immunisation in developing countries? : a systematic review of the literature. Applied Health Economics and Health Policy, 4 (3). pp. 165-173.

Raithatha, N and Smith, RD (2004) Paying for statins. British Medical Journal, 328 (7436). pp. 400-402.

Raithatha, N and Smith, RD (2004) Disclosure of genetic tests for health insurance: is it ethical not to? The Lancet, 363 (9406). pp. 395-396.

Raithatha, N and Smith, RD (2004) But why cant i have a statin doctor? The economics and ethics of offering patinet choice. British Medical Journal, 328. pp. 400-402.

Smith, RD (2004) A randomised controlled trial of domiciliary medication review by pharmacists in the elderly. In: Faculty of Public Health Conference, Edinburgh.

Smith, RD (2004) Contingent valuation in health care: is there more to it than just health status. In: Fifth International Conference on Health Economics, London.

Smith, RD (2004) The reliability of willingness to pay for changes in health status. In: Fifth International Conference on Health Economics, London School of Economics.

Smith, RD (2004) Sensitivity to scale in contingent valuation: the importance of the budget constraint. In: Fifth International Conference on Health Economics, London School of Economics.

Smith, RD (2004) Contingent valuation in health care: is there more to it than just health status? In: Health Economist Study Group, Glasgow.

Smith, RD (2004) Its not what you do, its the way that you do it: a comparison of questionnaire formats and modes of administration for contingent valuation in health care. In: Health Economist Study Group, Glasgow.

Smith, RD (2004) Making sense of the economic evidence in understanding the value of interventions for severe asthma. In: Health Economist Study Group, Glasgow.

Smith, RD (2004) The $64,000 or ($30,000) question: willingness to pay for a QALY from a UK perspective. In: Ninth Annual International meeting of the International Society for Pharmacoeeconomics and Outcomes .

Smith, RD (2004) A randomised controlled trial of domiciliary medication review by pharmacists in the elderly. In: Society for Social Medicine, Birmingham, UK.

Smith, RD (2004) Foreign direct investment and trade in health services: a review of the literature. Social Science and Medicine, 59 (11). pp. 2313-2323.

Smith, RD and Adil, M (2004) Measuring the globalisation of health services: a possible index of openness of country health sectors to trade. Research Report. UNSPECIFIED.

Smith, RD, Thorsteinsdóttir, H, Daar, AS, Gold, ER and Singers, PA (2004) Genomics knowledge and equity: a global public goods perspective of the patent system. WHO Bulletin, 82 (5). pp. 385-389.

Smith, Richard (2004) The Reliability of Willingness to Pay for Changes in Health Status. Applied Health Economics and Health Policy, 3 (1). pp. 35-38.

Thorsteinsdóttir, H, Daar, AS, Smith, RD and Singer, PA (2004) Do patients encourage or inhibit genomics as a global public good? In: Populations and Genetics: Legal and Socio-Ethnical Perspectives. UNSPECIFIED, pp. 487-504.

VanderBruggen, T, Jansen, W, Monnet, DL, Smith, RD, Verhoef, J and Fluit, A (2004) Estimating the public health cost of antimicrobial resistance in Europe: the example of MRSA [Report to the European Commission]. Research Report. UNSPECIFIED.

Chanda, R, Smith, RD and Drager, N (2003) A framework for country analysis of commercial presence. Globalization, Trade and Health Working Paper, Strategy Unit, Director General's Office.

Coast, J and Smith, RD (2003) Solving the problem of antimicrobial resistance: is a global approach necessary? Drug Discov Today, 8 (1). pp. 1-2.

Coast, J and Smith, RD (2003) Antimicrobial resistance: cost and containment. Expert Review of Anti-Infective Therapy, 1 (2). pp. 241-251.

Gobrecht, J, Smith, RD and Drager, N (2003) Measuring Trade in Health Services - Globalization, Trade and Health Working Paper. Strategy Unit, Director General's Office, WHO.

Mortimer, D, Smith, RD, Coast, J, Millar, MR and Mills, A (2003) Development of an economic model of antimicrobial resistance. Report to: Department of Child and Adolescent Health Development, World Health Organization. Research Report. UNSPECIFIED.

Singer, P, Thorsteinsdóttir, H, Daar, A and Smith,, RD (2003) Genomics knowledge. In: Global Public Goods for Health: a health economic and public health perspective. Oxford University Press, pp. 142-163. ISBN 0198525443

Smith, RD (2003) What does economics have to offer in the war against antimicrobial resistance. In: The resistance phenomenon in microbes and infectious disease vectors: implications for human health and strategies for containment. National Academy Press. ISBN 0309088542

Smith, RD (2003) Global public goods for health: use and limitations. Oxford University Press, pp. 250-269. ISBN 0198525443

Smith, RD (2003) A Computable General Equilibrium Model of the Economic Impact of Antimicrobial Resistance,. In: Canmore, Canada.

Smith, RD (2003) Antimicrobial resistance: a micro-economic modeling approach. In: Fourth World Congress of the International Health Economics Association, San Francisco.

Smith, RD (2003) Assessing life in the elderly : a comparison of two utility measures. In: Fourth World Congress of the International Health Economics Association, San Francisco.

Smith, RD (2003) Bayesian estimates of willingness-to pay for health benefit. In: Fourth World Congress of the International Health Economics Association, San Francisco.

Smith, RD (2003) A Computable General Equilibrium Model of the Economic Impact of Antimicrobial Resistance. In: Fourth World Congress of the International Health Economics Association, San Francisco.

Smith, RD (2003) Willingness to pay and senstivity to scale: the 'income effect'. In: Fourth World Congress of the International Health Economics Association, San Francisco.

Smith, RD (2003) Antimicrobial resistance: a micro economic modeling approach. In: International Society for Technology Assessment in Health Care (ISTAHC) Conference, Canmore, Canada.

Smith, RD (2003) Assessing quality of life in the elderly: a comparsion of two utility measures. In: International Society for Technology Assessment in Health Care (ISTAHC) Conference, Canmore, Canada.

Smith, RD (2003) The 'reference price' effect in WTP studies: reality or illusion? In: International Society for Technology Assessment in Health Care (ISTAHC) Conference, Canmore, Canada.

Smith, RD (2003) Willingness to pay and sensitivity to scale the 'income effect'. In: International Society for Technology Assessment in Health Care (ISTAHC) Conference, Canmore, Canada.

Smith, RD (2003) Trade in health services: commercial presence-foreign direct investment. Globalization, Trade and Health Working Paper, Strategy Unit, Director General's Office.

Smith, RD (2003) Construction of the contingent valuation market in health care: a critical assessment. Health Economics, 12 (8). pp. 609-628.

Smith, RD (2003) Global public goods and health. WHO Bulletin, 81 (7). p. 475.

Smith, RD (2003) What does economics have to offer in the war against antimicrobial resistance? In: Exploring the Challenges and Consequences of Resistances: Factors in Microbes, Vectors, and the Human Host. UNSPECIFIED.

Smith, RD and Coast, J (2003) Antimicrobial Drug resistance. In: Global Public Goods for Health: a health economic and public health perspective. Oxford University Press. ISBN 0198525443

Smith, RD and Singer, P (2003) Genomics and Global Public Goods for Health. In: Global Public Goods for Health. WHO. ISBN 0198527985

Smith, RD and Sommers, T (2003) Assessing the economic impact of communicable disease outbreaks: the case of SARS. Strategy Unit, Director General's Office, WHO.

Thorsteinsdóttir, H, Daar, AS, Smith, RD and Singer, PA (2003) Do patents encourage or inhibit genomics as a global public good? In Knoppers BM, Caulfield TA and Laberge C (eds), DNA Sampling: Ethical, Legal and Social Issues. In: UNSPECIFIED UNSPECIFIED.

Thorsteinsdóttir, H, Daar, AS, Smith, RD, Singer, PA, Larranaga, N, Barricarte, A and Chirlaque, MD (2003) Genomics--a global public good? The Lancet, 361 (9361). pp. 891-892.

Woodward, D and Smith, RD (2003) Global Public Goods For Health: concepts and issues. In: Global Public Goods for Health: a health economic and public health perspective. UNSPECIFIED.

Yeung, RY, Smith, RD and McGhee, SM (2003) Willingness to pay and size of health benefit: an integrated model to test for 'sensitivity to scale'. Health Economics, 12 (9). pp. 791-796.

Coast, J and Smith, RD (2002) Economics of antimicrobial resistance: a brief overview. Journal of Drug Assessment, 5. pp. 3-10.

Coast, J, Smith, RD, Karcher, AM, Karcher, A-M, Wilton, P and Millar, M (2002) Superbugs II: how should economic evaluation be conducted for interventions which aim to contain antimicrobial resistance? Health Economics, 11 (7). pp. 637-647.

Smith, RD (2002) Assessing life in the elderly : a comparison of two utility measures. In: Fifth Annual European Conference Congress on the International Society for Pharmacoeconomics and Out.

Smith, RD (2002) Assessing life in the elderly : a comparsion of two utility measures. In: Health Economists Study Group, Brunel.

Smith, RD (2002) Diminishing marginal willingness to pay for health benefit: internal and external tests of scope. In: Health Economists Study Group, Brunel.

Tyler, J and Smith, RD (2002) The evaluation of prevention, carers and partnership projects: methodology development and scheme evaluation.

Wilton, P and Smith, RD (2002) Devolved budgetary responsibility in primary care: a cross-country assessment of the impact on efficiency. European Journal of Health Economics, 3 (1). pp. 17-25.

Wilton, P, Smith, RD, Coast, J and Millar, M (2002) Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness. Journal of Health Services Research and Policy, 7 (2). pp. 111-117.

Yago, M, Smith, RD, Coast, J and Millar, MR (2002) Development of an economic model of antimicrobial resistance. Report to: The Nuffield Trust, London. Research Report. UNSPECIFIED.

Coast, J and Smith, RD (2001) Antimicrobial Resistance: Can economics help? Eurohealth, 7 (2). pp. 32-33.

Olsen, JA and Smith, RD (2001) Theory versus practice: a review of 'willingness-to-pay' in health and health care. Health Economics, 10 (1). pp. 39-52.

Smith, RD (2001) Disentangling value: assessing the benefits of preventing the emergence and transmission of antimicrobial resistance. In: International Conference on the Economics of Infectious Disease, London.

Smith, RD (2001) Context in a Contingent Valuation: An examination of community valuation of three government services. In: Third World Congress of the International Health Economics, York.

Smith, RD (2001) Economics, interventions and antimicrobial resistance. In: Third World Congress of the International Health Economics, York.

Smith, RD (2001) The relative sensitivity of willingness-to-pay and time-trade-off to changes in health status: an empirical investigation. Health Economics, 10 (6). pp. 487-497.

Smith, RD and Coast, J (2001) Global Responses to the Growing Threat of Antimicrobial Resistance. Research Report. UNSPECIFIED.

Smith, RD, Coast, J, Millar, M, Wilton, P and Karcher, A-M (2001) Interventions against antimicrobial resistance - a review of the literature and exploration of modelling cost effectiveness. Research Report. UNSPECIFIED.

Smith, RD and Salter, BG (2001) Citizen, consumer or both? Reconceptualising demand in health care. In: UNSPECIFIED Ashgate Publishing Ltd., pp. 146-457. ISBN 0754616126

Wilton, P, Smith, RD, Coast, J, Millar, M and Karcher, A (2001) Directly observed treatment for multidrug-resistant tuberculosis: an economic evaluation in the United States of America and South Africa. International Journal of Tuberculosis and Lung Disease, 5 (12). pp. 1137-1142.